Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142775 | 0.88 | PDE7A (0.42) | HTR1DALDH1A1FAAH | |
| SCHEMBL4147542 | 0.88 | SIGMAR1 (0.38) | HTR1DCYP3A4 | |
| SCHEMBL4137087 | 0.86 | HTR1D (0.41) | HTR1DCYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL4140801 | 0.84 | HRH3 (0.34) | CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2 | |
| SCHEMBL4135443 | 0.84 | ALDH1A1 (0.47) | HTR1DCYP11B2ALDH1A1 | |
| SCHEMBL4141014 | 0.84 | ALDH1A1 (0.47) | HTR1DCYP11B2ALDH1A1 | |
| SCHEMBL4135445 | 0.84 | ALDH1A1 (0.47) | HTR1DCYP11B2ALDH1A1 | |
| SCHEMBL4136016 | 0.83 | HTR1D (0.41) | HTR1DCYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL4133407 | 0.82 | HTR1A (0.43) | HTR1DCYP1A2CYP2C9GRIN2BHTR1A | |
| SCHEMBL4144848 | 0.82 | ALDH1A1 (0.39) | HTR1DCYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HTR1D 25/4885CYP1A2 1220/4885CYP3A4 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.